GLP-1 receptor agonists such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) have transformed the pharmacologic treatment of obesity and Type 2 diabetes. Metabolic surgery — including procedures that may use the MagDI™ System — addresses similar physiology through anatomic and hormonal changes. This article compares the two approaches at a high level.
Mechanism
- GLP-1 medications — weekly injection; appetite suppression, delayed gastric emptying, improved insulin secretion.
- Metabolic surgery — anatomic and neurohormonal changes that alter satiety, gut-brain signaling, and nutrient handling.
Durability
Weight loss with GLP-1 medications typically requires continuous use; published data show meaningful weight regain when the medication is stopped. Metabolic surgery has shown more durable weight loss in long-term studies, though some patients experience weight regain over time.
Side effects and risks
GLP-1 medications can cause nausea, GI side effects, and other documented adverse effects. Metabolic surgery carries surgical risk including bleeding, leak, and rare serious complications. The published 30-day morbidity in the OCC outcomes cohort is 1.2% with zero reported mortalities.
Cost considerations
GLP-1 medications often involve recurring long-term cost. Metabolic surgery is a one-time procedure with follow-up care.
What we will not say
We do not tell patients to start or stop any medication. Medication changes should only be made in consultation with your prescribing healthcare professional.